Comparative Pharmacology
Head-to-head clinical analysis: LOTRIMIN versus OXISTAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOTRIMIN versus OXISTAT.
LOTRIMIN vs OXISTAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clotrimazole inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Oxiconazole is an azole antifungal that inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Clotrimazole 1% cream or solution applied topically to affected area twice daily for 2-4 weeks. For vaginal tablets: 100 mg intravaginally once daily for 7 days or 500 mg single dose. For troches: 10 mg troche dissolved slowly in mouth five times daily for 14 days.
Apply topically once daily for 2 weeks (tinea pedis, tinea cruris, tinea corporis) or 4 weeks (tinea versicolor).
None Documented
None Documented
Terminal elimination half-life is approximately 20-50 hours. Dose adjustments not required in renal impairment, but caution in hepatic impairment.
Terminal elimination half-life is 20–30 hours, supporting once-daily topical application.
Approximately 70% of absorbed dose is excreted in feces as unchanged drug and metabolites; about 20% is excreted renally as metabolites with less than 1% unchanged. Biliary excretion is a minor route.
Primarily hepatic metabolism; <1% excreted unchanged in urine; biliary/fecal elimination accounts for ~75% of dose.
Category C
Category C
Topical Antifungal
Topical Antifungal